A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

Treatment options have grown increasingly complex for patients with follicular lymphoma. In this commentary, I share how I approach individualizing and sequencing therapy for patients with newly diagnosed and relapsed/refractory disease.

John P. Leonard, MD Released: November 1, 2021

How are you managing patients with mantle cell lymphoma? Read this commentary for my approach.

Brad S. Kahl, MD Released: November 12, 2021

Now that ibrutinib and zanubrutinib are both approved by the FDA in the relapsed/refractory setting for marginal zone lymphoma, where do we sequence and how do we choose between these BTK inhibitors? Read this commentary for my approach.

John P. Leonard, MD Released: November 2, 2021

How are you managing patients with diffuse large B-cell lymphoma? Read this commentary for my approach.

Julie M. Vose, MD, MBA Released: December 1, 2021

How are you managing patients with EBV-associated posttransplant lymphoproliferative disease? Read this commentary for my approach.

Julie M. Vose, MD, MBA Released: December 6, 2021